# Nuclide record navidea (company). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/companies/navidea/>
  a schema:Organization ;
  nuclide:kind "company" ;
  schema:identifier "navidea" ;
  schema:name "Navidea Biopharmaceuticals"@en ;
  schema:alternateName "Navidea"@en, "Neoprobe Corporation"@en ;
  schema:description "Navidea developed technetium-99m tilmanocept (Lymphoseek), the radiotracer approved in 2013 for mapping sentinel lymph nodes in breast cancer, melanoma and head and neck cancer."@en ;
  schema:url <https://nuclide.cc/companies/navidea/>, <https://www.navidea.com> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Navidea_Biopharmaceuticals> ;
  schema:citation <https://clinicaltrials.gov/search?lead=Navidea%20Biopharmaceuticals>, <https://en.wikipedia.org/wiki/Navidea_Biopharmaceuticals> ;
  nuclide:tag "ctgov-sponsor" ;
  schema:addressCountry "US" ;
  nuclide:related <https://nuclide.cc/isotopes/tc-99m/> ;
  nuclide:drugs <https://nuclide.cc/drugs/tilmanocept-tc99m/> .